Trial
NCT06626633
2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML
Phase ISUSPENDEDOPERATIONALConfidence: HIGH
Sponsor
University of Maryland, Baltimore
Collaborators
—
Condition
Acute Myeloid Leukemia
Intervention
CRD3874
Why stopped
Pharmaceutical Company withdrew support and investigational product
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-12